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Abstract Since the introduction of chemotherapy for
cancer treatment in the early 20th century considerable
efforts have been made to maximize drug efficiency and at
the same time minimize side effects. As there is a great
interpatient variability in response to chemotherapy, the
development of predictive biomarkers is an ambitious aim
for the rapidly growing research area of personalized
molecular medicine. The individual prediction of response
will improve treatment and thus increase survival and life
quality of patients. In the past, cell cultures were used as
in vitro models to predict in vivo response to chemother-
apy. Several in vitro chemosensitivity assays served as
tools to measure miscellaneous endpoints such as DNA
damage, apoptosis and cytotoxicity or growth inhibition.
Twenty years ago, the development of high-throughput
technologies, e.g. cDNA microarrays enabled a more
detailed analysis of drug responses. Thousands of genes
were screened and expression levels were correlated to
drug responses. In addition, mutation analysis became
more and more important for the prediction of therapeutic
success. Today, as research enters the area of -omics
technologies, identification of signaling pathways is a tool
to understand molecular mechanism underlying drug
resistance. Combining new tissue models, e.g. 3D organoid
cultures with modern technologies for biomarker discovery
will offer new opportunities to identify new drug targets
and in parallel predict individual responses to anticancer
therapy. In this review, we present different currently used
chemosensitivity assays including 2D and 3D cell culture
models and several –omics approaches for the discovery of
predictive biomarkers. Furthermore, we discuss the
potential of these assays and biomarkers to predict the
clinical outcome of individual patients and future
perspectives.
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Introduction
In the past decades, research in the field of molecular
profiling of cancer was strongly affected by the rapid
development of technologies. The complex disease-related
alterations in the molecular networks, that are associated
with response to chemotherapy, result in significant clin-
ical heterogeneity among individual tumors and patients.
A detailed and comprehensive understanding of drug
response mechanisms is essential to ultimately guide a
molecular based personalized anticancer therapy. Today,
the complex networks of cellular mechanisms in cancer
cells are just incipiently understood. Progress in all fields
of cancer research, ranging from the optimization of
cellular models and chemosensitivity assays over proteo-
mics to genomics is revealing more and more facets of
determinants of individual chemosensitivity. Besides
studies in patients and xenograft models of tumors,
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in vitro cell cultures are the most commonly used systems
for the analysis of cellular responses to drug treatment. A
whole spectrum of cellular models ranging from second-
ary cell lines and primary mixed cultures over
multicellular spheroids to organoid cultures are being
used in cancer research. These models are being con-
stantly optimized to mimic the origin tumor and tumor
microenvironment as close as possible. Cell culture
models are the basis for the molecular analysis of indi-
vidual drug response. Relatively common approach to
measure cellular chemosensitivity is the use of various
in vitro chemosensitivity assays, which basically only
detect the sum of all specific cellular drug effects. This
measurement of drug effects on cell viability is deeply
integrated in basic research, as well as in the clinical
setting for the general determination of chemoresistance
of a patients‘ tumor. To investigate the molecular details
of individual drug responses, genomic and proteomic
methods were integrated in cancer research. These tech-
nologies enable comprehensive investigation of the multi-
factorial mechanisms underlying individual drug response
by the simultaneous analysis of thousands of genes or
proteins. This huge amount of generated data can be
merged to a complex picture of molecular networks and
will significantly contribute to the understanding of the
diversity in individual drug response. The technical
advances in all areas are enhancing the amount of infor-
mation output rapidly and ultimately the interconnection
of all fields of research should be able to combine
molecular attributes to individual, molecular signatures of
chemosensitivity. The molecular characterization of
patients will shift the concept of anticancer therapy from
standardized treatment of patients to specialized treatment
concepts for molecular-defined subgroups of patients
(Fig. 1). In the future, this individualization of anticancer
therapy will increase survival and life quality of patients,
by being able to provide maximal effective therapies and
sparing them from uneffective therapies and side effects.
Cellular models
The prediction of response to chemotherapy at the molec-
ular level is currently mostly based on data derived from
in vitro experiments (Fig. 2). Besides studies in patient
populations and xenograft models of tumors, cell cultures
are the most commonly used in vitro systems for the ana-
lysis of cellular responses to drug treatment. Various types
of cell culture models exist. These models differ in their
ability to reflect the in vivo situation, which is of great
importance for further translation of results to the clinical
setting.
As a result of the gain in knowledge of cancer-specific
signaling networks and metabolic pathways, it became
obvious, that cell behavior is strongly influenced by the
microenvironment of the cell [1, 2]. These findings had
great impact on the development of in vitro cell culture
models and their use in drug discovery and translational
research. 2D cell cultures are the oldest and widely used
models in cancer research, comprising mainly clonal-sec-
ondary and infrequently primary cell lines. Clonal-
secondary cell lines are inexpensive in acquisition and easy
to handle. Due to their ability to grow infinitely, they are
well applicable in high-throughput screenings, suitable for
genetic modification and good sources for preparations of
cell components (e.g. mitochondrial-, membrane-, nuclear
fractions). However, the preparation of cell lines from a
tumor, results in loss of the 3D in vivo structure and in
diversity of cell populations, thus these models only partly
represent the origin tumor. Alongside the progress in lab-
oratory technologies, the design of more and more
extensive in vitro models became possible. Based on first
attempts to rebuild 3D tumor structures, using secondary
cell lines and natural as well as artificial extracellular
matrices (ECM’s), the techniques for the preparation of
such models rapidly advanced. Currently, the mixed cul-
ture of different cell types, the use of feeder layer cell lines
and the induction of angiogenesis in these 3D cell culture
Fig. 1 Schematic illustration of
the concept of the realization of
personalized medicine by
molecular analysis
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systems are main improvements in this area of research.
Nonetheless, these models represent artificial microenvi-
ronments and many features of an original tumor cannot
yet be displayed. Complex models such as in vitro 3D-
organoid cell cultures or xenografts currently best display
the characteristics of an in vivo tumor. The cultivation of
vital tumor tissue slices, for example, enables drug testing
in a natural tumor environment and has the capability to
reveal tissue composition dependent cellular responses to
anticancer therapy. Xenografts also have the ability to
mimic the in vivo microenvironment of a tumor in a
physiological context, regarding nutrient supply, angio-
genesis etc. However, using this model, differences in
metabolism, body size and genetic background between the
host species and humans have to be considered.
In summary, organoid cell cultures and xenografts rep-
resent valuable ‘‘bridge models’’ between in vitro cell lines
and the clinical in vivo setting. The choice of a cell culture
model for research should depend on the application in the
study design and cost-benefit ratio.
Primary and secondary cell lines
Over 60 years ago, the first human clonal cancer cell line
was established from a patient’s tumors. Today, human
tumor-derived clonal cell lines are able to grow in vitro, are
easy to handle and thus they find wide application. Thou-
sands of cell lines from diverse tumor entities can be
purchased from different suppliers (e.g) [3, 4]. These cell
lines are characterized and usually delivered including
basic data, such as genetic profile (STR), morphology,
doubling time, cytogenetics and references, by which
additional data can be received using literature search.
Being such robust and easy to handle models, secondary
cell lines are a preferred starting point for the analysis of
cellular mechanisms, e.g. resistance to anticancer therapy
and signaling pathways. These models are also routinely
used in versatile applications, e.g. testing of efficacy of
compounds, examination of metastasis mechanisms, prep-
aration of cellular compartments, extraction of proteins and
DNA. Furthermore, secondary cell lines are well suited for
artificial manipulation of cell characteristics, such as
expression of mRNAs and proteins, mutations (knock-in)
and modulation of chemosensitivity.
For example, approaches to understand acquired drug
resistance are cancer cell lines with established drug
resistance. Continuous exposure of these drug-sensitive
cell lines to anticancer therapeutics in vitro, selects for the
relatively rare drug-resistant clones, which are then further
raised to a chemoresistant sub clone cell line. Comparative
analysis of properties of the parental drug-sensitive cell
lines and the selected drug-resistant cell lines has the
potential to identify specific molecular mechanisms of drug
resistance [5]. Hence, transformed cell lines and their
parental counterparts are also commercially available and
represent artificial, but defined models for the investigation
of determinants of chemosensitivity.
Nowadays, secondary cell lines are integrated in huge
compound screening programs for drug discovery and
research programs to understand the underlying mechanism
of individual response to chemotherapy. Secondary cell
lines fulfill all requirements for implementation in high-
throughput screenings, enabling the rapid screening of
large panels of compounds. The National Cancer Institute
60 (NCI60) platform was the first high-throughput cancer
cell line screening program and therefore triggered the
development of adequate techniques. The experimental
methods had to be adapted to the requirements of eco-
nomic, high-throughput screenings, e.g. high-content data
mining, automation of handling liquids, miniaturization of
cell culturing and drug testing procedures. A major finding
of the program was that compounds with similar patterns of
cell line chemosensitivity tend to have common mecha-
nism of action, which led to the development of new
algorithms for data analysis and adaption of study designs.
The NCI60 anticancer drug discovery program was
Fig. 2 Exemplary illustration
of different cellular models used
in translational research
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reviewed in detail by Shoemaker [6], who highlighted its
history and methodology. Learning from the NCI60 expe-
riences, the Cancer Chemotherapy Center of the Japanese
Foundation for Cancer Research (JFCR) established the
JFCR-39 platform. This panel of 39 human tumor-derived
cell lines included a subset of the NCI60 cell lines and
additional gastric cancer cell lines [7]. A new algorithm for
data analysis enabled the comparison of newly screened
compounds with previously screened compounds to dis-
criminate between new or previously described modes of
action. Using the COMPARE algorithm and advanced data
mining techniques, several new anticancer agents [8–11]
were identified.
In drug discovery or predictive biomarker studies for the
introduced ‘targeted anticancer therapeutics’, small panels
of cancer cell lines cannot display the clinical activities of
these compounds, which are often limited to small sub-
groups of molecular-defined patients. Taking this into
account, high-throughput screenings are now being adapted
to much larger panels of cell lines. To capture the genetic
heterogeneity among diverse cancers, Mc Dermott and
colleagues [12] developed an automated platform for the
screening of the chemosensitivity of 500 solid cancer cell
lines to kinase inhibitors. In this study, they observed the
expected response rates with only small subgroups of cell
lines showing responses to particular compounds. There-
fore, a comprehensive cancer cell line platform was
established, currently including 1,200 cancer cell lines.
Due to the fact that only around 80 % of those secondary
cancer cell lines are adaptable to high-throughput screen-
ing, mostly caused by technical limitations such as
insufficient doubling times or atypical culture require-
ments, this panel is referred to as the Center for molecular
Therapeutics 1000 (CmT1000) [13]. This cell line panel is
currently being used to investigate the genetic determinants
for chemosensitivity. First results from this large data sets
showed that tumor-derived cell lines recapitulate clinical
findings concerning responses to targeted inhibitors [14].
Another, very recent approach in generating primary
cell lines for in vitro experiments has been introduced by
Lui et al. [15]. This approach initially comprised a method
to indefinitely extend the life span of primary human
keratinocytes using both fibroblast feeder cells and a Rho-
associated kinase (ROCK) inhibitor, and is also efficiently
applicable to establish cell cultures from human and rodent
tumors. This innovative technique provides significant
opportunities for cellular diagnostics and molecular thera-
peutics (drug profiling), expands the value of biobanking
and has the potential to greatly improve personalized
medicine.
A general disadvantage of secondary cell lines is that
they only represent one cell from a diverse tumor micro-
environment which resembles the capabilities necessary for
adapting to in vitro culture. It is still unclear in which
manner adaption to in vitro culturing and multiple pas-
saging influences cell characteristic/behavior. The
establishment and cultivation of primary mixed single cell
cultures always have been quite complicated [16]. Primary
mixed cell cultures isolated from patient’s tumors represent
a wide spectrum of cell types abundant in vivo. This
diverse mixture mainly consists of different epithelial- and
mesenchymal cancer cells, tumor associated stroma and
immune cells [17, 18]. Therefore, these primary cell cul-
tures more closely reflect the in vivo situation than
secondary, clonal cell lines. However, several difficulties
are still to overcome, while establishing primary mixed
cultures. The basis for the preparation of primary, mixed
cell cultures is vital tumor tissue and experience in cell
culture handling. Besides the quality of tumor tissue, the
method for preparation of single cells from a tumor, the
surface preparation of cell culture dishes and finally the
composition of the culture media are also essential
parameters for a successful establishment of primary mixed
cultures. The artificial shifts in and losses of cell popula-
tions, due to unnatural in vitro culturing and passaging,
limits the maximal diversity of cell types to low passage
primary, mixed cultures. Most studies using primary cells
prepare cell cultures shortly after tumor resection and
disseminate cells directly for experiments. Studies regard-
ing the in vitro chemosensitivity of primary cells were
conducted in different tumor entities e.g. small cell lung
cancer [19], colorectal cancer [20, 21], gastric cancer [22],
Leukemia [23, 24], ovarian cancer [25–27] and head and
neck cancer [28, 29]. One limiting factor is that, the
diversity of cell types will decrease during in vitro culti-
vation, due to the dissimilar ability of different cell types to
proliferate in vitro and survive passaging. Another issue
limiting the predictive value of these cell cultures is the
loss of the 3D architecture of the origin tumor. Although
the in vitro analysis of cultured cell lines is associated with
artifacts related to effects attributed to a non-physiological
environment and long-term passage in culture, it was
shown that cancer cell lines retain most of the genomic
features of the primary tumor [30, 31]. This has not yet
been shown for proteomic features of cancer cell lines. The
awareness of the importance of the tumor microenviron-
ment and the three-dimensional aspects of solid tumors, in
the response to anticancer therapy has initiated efforts to
display these features in vitro more accurately [32–34].
There are also several other important factors to take in
regard to mimic the in vivo microenvironment of a tumor
in vitro. For example, a whole field within cancer research
is dedicated to the investigation of hypoxia, which is
defined as inadequate oxygen supply to cells and tissues, in
solid tumors and implications on anticancer treatment [35–
40]. The oxygen concentration of 21 %, used in most
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in vitro culture systems is not physiological in regard to the
limited oxygen supply of cells within a solid tumor.
Multicellular spheroids
Since it has been shown that the cellular signaling network,
e.g. regulation of apoptosis is influenced by 3D cell orga-
nization and multicellular complexity, new cell culture
models for a more realistic investigation of tumor cell
behavior ex vivo are urgently needed [41]. To establish
such models, it is necessary to maintain or reconstitute an
environment which closely resembles the tumor in vivo.
One of the first approaches of rebuilding the 3D microen-
vironment during in vitro cultivation and drug testing was
the development of a culture model called ‘‘Spheroids’’. In
1970, the first spheroid model was devised by Sutherland
[42]. Meanwhile, spheroids have been grown from a vari-
ety of normal and tumor cell lines and used in different
assays, to study anticancer therapy efficiency as well as 3D
cellular interactions [43, 44]. Single cell cultures were used
to establish an organoid-like 3D model using different
techniques [45, 46]. These different culture techniques
include various artificial as well as natural ECM‘s [47, 48]
and mechanical methods to generate defined, roundly
shaped cell clusters. Matrices, such as agarose, collagen,
gelatin or matrigel allow the establishment of culture sys-
tems with well-defined geometry, wherein the 3D structure
affects interactions between cells. This usage of 3D
matrices has been reported to show fruitful results in
recapitulating tissue functions in 3D [49, 50]. Besides
various cancer cell lines, cell types like Madin–Darby
canine kidney cells and fibroblasts, have also been moni-
tored in 3D contexts and have provided valuable insight
into the basic molecular mechanisms of polarity, adhesion,
cell migration and response to anticancer therapy [51–53].
Numerous studies have documented differences in cancer
drug sensitivity between cells cultured in monolayers and
those grown in 3D cultures [54–56]. Previous studies have
shown that certain drugs are more effective in 3D cell
culture systems [57–60], although other drugs showed
greater activity in the 2D cell culture systems [61, 62].
These days, fewer than 100 human tumor cell lines have
been reported to grow in spheroid cultures [63]. Platforms
based on tumor spheroids have been developed and are
being used for analysis of individual chemosensitivity and
secondary screening of potential new anticancer com-
pounds [64, 65]. The application of spheroids in drug
screenings has been reviewed by Friedrich and colleagues
[66]. However, it remains to be demonstrated comprehen-
sively that chemosensitivity data derived from 3D cell
cultures captures clinically relevant responses more pre-
cisely than standard 2D cultures. Furthermore, these
systems cannot completely mimic the complex tissue
architecture and the high degree of variability seen in
individual tumors.
Organoid cultures
It has been shown that signaling and metabolic pathways in
cell lines have distinctly different expression patterns
compared to tumor tissues. Pathways in cell lines tended to
be upregulated compared to tumor tissue with exceptions in
genes involved cell adhesion, ECM-receptor interaction
and focal adhesion [34, 67]. As discussed before, spheroids
are a good approximation to the in vivo tumor, but still lack
the natural tumor environment, including the state of
receptors and corresponding extracellular signaling
between diverse cell types naturally being present in the
tumor. Therefore, the development of in vitro organoid cell
culture models was an essential step for translational
research. First experiments were performed in 1967 by
Matoska and Stricker, using tumor cubes of approximately
1 mm3 [68] for in vitro culturing. Later, an in vitro histo-
culture system, using a native-state collagen-sponge gel to
support the three-dimensional growth of tumor tissue sec-
tions was developed, called the Histoculture Drug-
Response Assay (HDRA) [69]. Features of the histoculture
system include the maintenance of three-dimensional tissue
architecture and the use of histological autoradiography or
colorimetric assays as endpoints for determination of
chemosensitivity [70, 71]. Ohie et al. [72] published a
protocol on the Method of the HDRA. The reliability and
utility of the HDRA were examined in several clinical
studies for different tumor entities, e.g. oral squamous cell
carcinoma [73], head and neck cancer [74], gastric cancer
[75], colorectal cancer [76] and ovarian cancer [77]. Up to
now, it has not been shown that the HDRA is also able to
predict efficiency of targeted drugs such as small molecules
and antibodies.
The past years have seen unprecedented developments
in the use of human tissue surrogates in vitro. Clevers et al.
[78] developed a technique in which adult stem cells,
originating from fresh tumor tissues, are embedded in a
three-dimensional matrix and allowed to self-organize into
epithelia of the respective organ of origin. The resulting
organoids represent the physiology of native epithelia
much better than traditional cell lines. Mini-guts, for
example, reproduce the epithelial architecture of small
intestine and colon [79, 80]. If combined with genetic
information and pharmacological profiles, such an orga-
noids could aid in identifying markers that predict a
patient’s drug response similar to the Cancer Cell Line
Encyclopedia [81].
Parallel to the development of tissue microtomes
enabling the preparation of thin slices of fresh tissue,
precision cut cancer tissue slices from tumor tissue have
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become more popular as ex vivo systems. It has been
shown, that cell viability of tissue slices was maintained in
in vitro culture for at least 4 days [82]. After treatment with
different compounds (chemotherapeutics, small molecules,
antibodies), slices can be fixed by immediate freezing or by
formalin. Frozen slices can be used for several assays, e.g.,
functional drug effects on viability (ATP), apoptosis
(activation of caspase 3/7), proliferation (BrdU) and signal
pathway analysis (activation of phosphoproteins). Forma-
lin-fixed slices can be utilized for immunohistochemical
analysis of target expression, drug effects and cell–cell
interactions. Furthermore, laser capture micro dissection
can be applied, allowing the separation of different cellular
compartments, for molecular analysis of pure cell popula-
tions. Viara and colleagues reported on a preclinical model
of organotypic culture for pharmacodynamic profiling of
human tumors [83]. This model demonstrates the ability to
detect pharmacological interventions ex vivo in a prese-
vered original cancer microenvironment. Due to the broad
spectrum of molecular techniques that can be implemented,
organoid cell culture models offer a unique opportunity to
understand the complex basis of cellular responses to
anticancer therapeutics of all groups, e.g. classical che-
motherapeutics, small molecules and therapeutic antibodies
[84]. Despite the advantages of the models, difficulties in
obtaining specimen and limited viability of these tissues in
culture over time represent major obstacles. The successful
cultivation of tissue slices is also dependent on tumor
entity, highly adapted culture conditions in terms of media
supplements and other culture techniques. In the future, the
use of miniaturized cell-based models that are specifically
engineered to closely reflect in vivo behavior can reduce
costs and add efficiencies to drug development, but most
importantly increase the accuracy of molecular prediction
of response to anticancer therapy.
Xenografts
Currently existing in vitro cancer cell culture models, such
as primary cell lines and organoid cultures are a solid basis
for molecular drug testing, but they do not reflect the
natural tumor environment in all facets. The final appli-
cation of anticancer drugs takes place in the in vivo
situation, in the patients. Since it is unethical to use patients
for preclinical research, xenograft cancer cell culture
models were developed to facilitate drug testing in vivo
and thus improve basic and translational research and
prediction of individual response to chemotherapy. Cancer
cell characteristics, such as chemosensitivity to anticancer
chemotherapy, are strongly affected by several para-
meters in a physiological, in vivo, situation. In contrast
to in vitro cell culture models, xenograft models offer
micro environmental conditions, e.g. tumor architecture,
angiogenesis, metastasis close to the real patient. The
injection of vital human cancer cells or even transplanta-
tion of human tumor fragments is therefore still essential to
study cancer in an in vivo situation [85, 86]. Among the
existing in vivo cell culture models, the mouse model is
widely used. It bears the relative advantages of good
availability, low space requirements, low cost, ease of
handling and fast reproduction rate. Mouse xenograft
models are extensively being used to study individual
response to anticancer therapy and drug development [87,
88]. Several studies on DNA and protein level were con-
ducted in mice xenografts to understand and predict
response to anticancer therapy. For example, gene
expression signatures and plasma protein biomarker have
been reported to predict efficiency of therapy ex vivo
[89–91].
But there are also multifaceted parameters affecting
outcome when conducting xenograft experiments, e.g. site
of implantation, growth properties and size of tumor at the
time treatment is administered, agent formulation, sched-
uling, dose and the selected endpoint for assessing activity.
A basic review on the mouse model in drug testing was
published by Mattern L. and colleagues in 1988 [92]. The
application of xenografts in drug testing has been reviewed
elsewhere in detail [93, 94]. Despite the relatively com-
prehensive ability of mice models to mimic the clinical
situation in patients, there are differences between mice
and humans which might have an impact on the predictive
value of this model [95]. Mice and humans obviously differ
largely in body size and lifespan. Although mice have a
similar incidence of cancer at the end of the life cycle, they
primarily develop cancers in mesenchymal tissues, e.g.
lymphomas and sarcomas. Most cancers in humans are of
epithelial-origin and lead to carcinomas. Furthermore, the
basal metabolic rate of mice is much higher, which results
in increased generation of reactive oxygen species, other
mutagens and also distinct metabolism of anticancer drugs
in mice from humans.
Xenografts may also fail to recapitulate immunological
aspects of tumor-stroma interactions that are present in
human patients. Cell signaling interactions between cancer
cells and host stromal cells may not occur properly due to
interspecies incompatibilities, e.g. interactions of ligands of
one species with receptors of the other [96, 99]. Those
incompatibilities may impact various characteristics of
tumors, e.g. drug response and metastatic behavior. [97,
100]. A short overview of the challenges of selecting the
‘right’ in vivo oncology pharmacology model and
improving the translation of these models to a clinical
setting was summarized by Firestone B, 2010 [98, 101].
Nonetheless, xenograft model are useful preclinical
models. The better these models are characterized on
genome and proteome level and by implementing the
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learning experience while using these models, the more
basic information on the individual response to anticancer
therapy will be gained.
Chemosensitivity assays
First experiments to determine the individual chemosen-
sitivity of tumor cells from cancer patients were made in
the mid-1950’s [102]. At that time, techniques for
chemosensitivity testing were developed on the basis of
well-known parameters such as colony forming ability,
growth inhibition or cell viability. In theory the overall
effects of cytotoxicity are the sum of all specific cellular
effects underlying multi-factorial mechanisms. Therefore,
in vitro chemosensitivity testing can potentially predict
response to anticancer therapy either by determination of
the death of all cancer cells or at least by complete growth
inhibition. Currently, chemosensitivity tests find wide
application in basic and translational research (Fig. 3).
The measurement of drug effects on cell viability is
integrated in basic research, for the detailed analysis of
efficiency and mode of action of drug candidates, as well
as in the clinical setting for the general determination of
chemoresistance of a patient’s tumor. Firstly, the mea-
surement of cancer cell chemosensitivity to miscellaneous
compounds with potential anticancer activity is the basis
of most drug discovery programs. Previous publications
described various phases of the development of an in vitro
anticancer drug screen, aimed at the identification of
compounds showing selective growth inhibition or cyto-
toxicity towards particular cell or tumor types [102, 103].
These screening programs require very robust, automated
chemosensitivity assays for the measurement of drug
effects on cancer cell viability or growth. Therefore, many
studies were performed comparing chemosensitivity
assays in regard to their sensitivity, reproducibility,
applicability to cancer cell lines of various origins and
potential for adaption to high-throughput [24, 104–106].
Secondly, in vitro chemosensitivity tests are, to some
extent, applied in the clinical setting to determine che-
moresistance in a patients‘ tumor. This may help to guide
individualized anticancer therapy, especially in second-
line treatment where the guidelines for therapy are not
always clearly defined [107].
In vitro chemosensitivity tests are not approved for
predicting or guiding therapeutic treatment of patients in
first-line therapy or routine use.
Implementation of cell viability assays in preclinical
drug testing
Besides a whole spectrum of assays, measuring events
indicating cell viability, the most often used cell viability
tests today in chemosensitivity testing are the MTT assay
[108], the FMC assay [109], the ATP-TCA [26, 110] and
SRB assay [102]. The four different assays measure cyto-
toxicity as a decrease of fundamental metabolic activity
(MTT assay, FMC assay) or by the reduction of essential
biomolecules (ATP assay) and cell mass (SRB assay). The
MTT tetrazolium salt colorimetric assay is based on the
metabolic reduction of 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT). The yellow tetra-
zolium salt MTT is converted by mitochondrial
dehydrogenases of metabolically active cells to an insolu-
ble purple formazan product. The optical density can be
detected by precise spectrophotometric measurement using
a plate reader [111]. The fluorometric microculture cyto-
toxicity assay (FMCA) measures fluorescence generated
from cellular hydrolysis of fluorescein diacetate (FDA) to
fluorescein by cytosolic esterase activity. The measured
enzyme activity in combination with indirect detection of
cell membrane damage is determined as parameters for cell
viability [112]. In the ATP-tumor chemosensitivity assay
(ATP assay) the intracellular ATP content is quantified by
measuring luminescence produced by a reaction of ATP
with luciferase and D-luciferin [113]. The assay allows for
a rapid, sensitive measurement of cellular ATP content.
ATP levels are linearly related to the number of viable cells
and increased with time in cell line cultures correlating
Fig. 3 Exemplary illustration
of different chemosensitivity
assays used in translational
research
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with growth kinetics [114]. The sulforhodamine B (SRB
assay) measures whole protein content for the detection of
viable cells. SRB is a pink aminoxanthene dye with two
sulfonic groups that bind to basic amino-acid residues
under mild acidic conditions. The binding of SRB is stoi-
chiometric, the amount of dye extracted from stained cells
is directly proportional to cell mass [27]. Using this assay
to determine cell growth or viability, one assumes that dead
cells either lyze, are removed during the procedure or
otherwise do not contribute to the colorimetric end point.
After fixation and staining procedures, tested cells can be
stored indefinitely, which also contributes to high-
throughput applicability. [115, 116]. The quantitative
results of these different chemosensitivity tests are similar,
although sensitivity varies. The lowest sensitivity was
found for the MTT assay. Here, a great number of cells
(25,000 cells/well) are needed to get reliable results. The
MTT assay is therefore not applicable when the tumor
biopsy is small. For the SRB assay [117] and the FMC
assay [27] around 2,000 cells/well are sufficient. The ATP
assay is reported to be able to detect down to ten cells/well.
In the past chemosensitivity assays have been technically
optimized continuously. Several new data analysis methods
were established, but the best comparison with the clinical
outcome has yet been achieved by the ‘‘sensitivity index’’
(SI) rather than the determination of the IC50 values or the
AUC index [118]. Currently, chemosensitivity is a basic
parameter for anticancer drug efficiency and in combina-
tion with several other read outs of drug effects integrated
in several drug discovery and preclinical drug testing
platforms.
For the initial large-scale drug screening program, called
the in vitro anticancer drug discovery project of the
National Cancer Institute (NCI), the sulforhodamine B
(SRB) assay has been chosen, because of its high level of
sensitivity, adaptability to high-throughput screening and
endpoint stability [115, 116]. This project tested 10,000 or
more samples per year in a manner that requires robust
technology for the analysis of several million individual
measuring points [119]. The SRB assay has mostly been
used for the measurement of cytotoxicity and cell growth in
high-throughput screening and basic research. Thus,
in vitro chemosensitivity data from this assay has rarely
been correlated to clinical outcome. By contrast, the
chemosensitivity data from cancer cells measured with the
MTT, FMC and ATP assays have been correlated with the
efficiency of anticancer therapy in a clinical setting.
Thereby, the ATP assay was preferably applied. Even
though not all cancer types can be examined because of the
above described limitations, correlations of the in vitro data
with clinical outcome were obtained for ovarian carcino-
mas [118], breast carcinomas [119], leukemia [120],
melanomas [107], colorectal carcinomas [121], lung
carcinomas [122] and gastric cancer [123]. Most results
exist for ovarian and breast carcinomas.
Besides monotherapies, two or more anticancer drugs
are often used in the in vivo clinical setting, sometimes
applied simultaneously in other cases sequentially, with
intermissions of one or more weeks. This situation can
hardly be mimicked by in vitro assays. Without the
knowledge of the pharmacokinetics of the single thera-
peutics applied in combination, the ratio of the substances
in the cells is unknown. Strong concentration-dependent
combination effects between different anticancer drugs
were observed [124, 125]. Synergistic, as well as antago-
nistic effects were found depending on the sequence of
drug treatment for the combination of paclitaxel and cis-
platinum [125, 126] and for combinations of platinum
compounds with paclitaxel and colchicines [127]. Besides
these limitations another point of concern is the drug
treatment time in vitro. During a short one-day incubation
time growth inhibition or colony forming ability cannot be
measured. An incubation time which allows the cells to
duplicate, at least 2 days to several weeks, is necessary for
the measurement of colony forming ability or growth
inhibition. Therefore the duplication time of the cancer
cells limits these methods. Furthermore, isolated primary
cancer cell cultures are difficult to cultivate in vitro. The
rate for successful cultivation and passaging of primary cell
cultures is low. Stromal cells, such as fibroblasts which
cannot be totally separated during isolation generally grow
faster than the cancer cells, which may lead to false results.
Serum free medium is reported to selectively reduce the
growth of fibroblasts [128]. Soft agar used in clonogenic
assays is also reported to hinder fibroblasts from forming
colonies [129]. However, it is not known how these
adapted cell culture conditions influence the growth and
characteristics of cancer cells. Especially in cancer types
where stromal cells influence cancer cell growth, e.g.
squamous cell carcinomas the in vitro data may not reflect
the in vivo situation.
The low response following physician choice especially
in the second or third line therapy, with little if any benefit
for the patients, demands in vitro chemosensitivity testing
which leads to higher response rates as published previ-
ously [128]. In addition, for the determination of drug
resistances these assays have shown convincing results [27,
130], which recommend the in vitro drug resistance mea-
surement routinely at least in the second-line therapy. In
the first-line therapy where the oncologist can choose
between several chemotherapies with equivalently effica-
cious response rates, a chemosensitivity assay directed
treatment could also be of advantage [128]. Several studies
reported weak to good correlations of in vitro to in vivo
data. Nonetheless, further studies were recommended for
clinical validation by most authors. The American Society
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of Clinical Oncology (ASCO) furthermore recommended
comparing patients, whose individual therapy resulted from
chemosensitivity testing with patients, whose therapy was
chosen empirically [131]. They did not recommend in vitro
chemosensitivity testing for chemotherapy guidance out-
side of clinical trials. Others contradicted the ASCO
especially because of the low number of studies considered
in their review article leading to insufficient conclusions
[132, 133].
In summary, chemosensititvity testing is deeply inte-
grated in basic drug testing and preclinical research.
Various methods are used to determine the sum of various
specific and unspecific drug effects on cells as decrease in
viability or cell death. The application of individualized
anticancer therapy based on in vitro chemosensitivity
testing in the clinical setting has been conducted using
several different laboratory methods [96, 134]. Correlations
of in vitro results with clinical outcome have indicated
predictive accuracies of 57–83 % for drug sensitivity and
[90 % for drug resistance [135–139]. Although studies
have demonstrated the predictive value of different
chemosensitivity assays, the insufficient number of pro-
spective randomized studies validating efficiency and
benefit has yet limited the routine application in the clinical
setting.
DNA damage and repair
Other multi-factorial endpoints such as DNA damage [140]
and DNA repair [141] were examined as parameters for
determining cancer cell chemosensitivity, as well. A broad
spectrum of anticancer drugs induces DNA damage which,
in turn, leads to cell death. Quantitative DNA damages
could therefore correlate with the clinical outcome of
patients treated with DNA damaging chemotherapeutics.
The comet assay, a method for the measurement of DNA
damage [140, 142] is used in chemosensitivity testing
because it is a quick, sensitive method that does not require
cell division. Also, only very few cells are needed, so that
cell numbers obtained by needle biopsies are in general
sufficient. Unger et al. [143] measured DNA damage
induced by cis- and carboplatin, doxorubicin and gemcit-
abin in primary cells of ovarian carcinomas. In parallel,
they measured the cell chemosensitivity and correlated
both parameters. Like others, they found a strong correla-
tion for the platinum compounds [144] but not for
doxorubicin and gemcitabin. Multiple targets of these cy-
tostatics may explain these results. For platinum
compounds the main cause of cytotoxicity is thought to be
the induced DNA damage [145]. In the future the comet
assay could become important in testing for platinum
resistances in patients especially in the second-line and
third-line therapies.
DNA damage is coupled with DNA repair, which has
been reported to be heterogeneous among individuals
[146]. For example, the determination of an individual
degree of induced DNA damage and repair capacity using
the comet assay [147] is therefore thought to be a prog-
nostic factor for chemosensitivity. Furthermore, DNA
damage response pathways have been shown in experi-
mental models to be associated with resistance or
sensitivity to DNA damaging agents. Teodoridis et al.
[148] examined potential associations of methylation pat-
terns of DNA damage response genes with response to
anticancer therapy. Over the last decade, there has been a
tremendous increase in the understanding of the mecha-
nisms of DNA damage detection, signaling, and repair, and
these findings have suggested therapeutic opportunities for
anticancer drugs that modulate these pathways [149, 150].
For example, there is a large body of experimental evi-
dence showing that DNA damage checkpoint kinase
inhibitors can enhance the efficiency of both conventional
chemotherapy and radiotherapy, and several agents have
entered clinical trials [151]. In the presence of DNA
lesions, cell cycle checkpoints and repair mechanisms are
being activated and a prominent route of cell elimination is
apoptosis [152]. Specific DNA lesions induced by DNA
damaging anticancer drugs that trigger apoptosis have been
identified. These include O6-methylguanine, base N-alky-
lations, bulky DNA adducts, DNA cross-links and DNA
double-strand breaks (DSBs). DNA damage induced cell
death by apoptosis has been reviewed by Roos et al. [153].
Apoptosis
In 1972, Kerr, Wyllie and Horvitz described the phenom-
enon of programed cell death and initially called this
process of natural cell death apoptosis. Since then, apop-
tosis has developed into an area of intense scientific interest
which encompasses the study of mechanisms involved in
mediating the cell biology of programed cell death. Two
major cell-intrinsic pathways for inducing apoptosis have
been identified. One begins with ligation of cell death
receptors, and the other involves mitochondrial release for
cytochrome c. Both pathways result in characteristic mor-
phological changes in nearly all cell types such as
membrane blebbing cell shrinkage, nuclear fragmentation,
chromatin condensation and chromosomal DNA fragmen-
tation. Many of the changes reflect the selective proteolytic
cleavage of various intracellular polypeptides (e.g., lamins,
caspases). Based on these alterations many different
in vitro methods have been devised to detect apoptosis.
Examples are the TUNEL (TdT-mediated dUTP Nick-End
Labeling) analysis [154], the DNA laddering analysis for
the detection of fragmentation of DNA in populations of
cells or in individual cells [155], the Annexin-V analysis
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that measures alterations in plasma membranes [156, 157],
and the activation of caspases (family of cysteine prote-
ases) [158]. In addition, apoptosis related proteins such as
p53, Fas, Bcl-2 and Bax are commonly analyzed to
understand details of the complex picture of the apoptotic
pathways.
Previous studies have demonstrated that a wide range
of anticancer agents, including chemotherapeutic agents,
hormones, and various biologicals, induce apoptosis in
malignant cells in vitro. Since apoptosis is a regulated
process, biochemical alterations that make cells more or
less susceptible to apoptosis might affect their sensitivity.
It has been proposed that tumor chemosensitivity to
anticancer drugs may partly be attributable to the degree
of activation of a genetic program for cell death. One of
the current models suggests that many different antican-
cer drugs such as doxorubicin, etoposide, and cisplatin
trigger apoptosis by inducing the synthesis of FasL,
which ligates Fas and activates caspase-8. However,
other studies have revealed many exceptions to this
model and propose that the majority of anticancer drugs
initiate apoptosis by the cytochrome c/Apaf-1/caspase-9
pathway resulting in mitochondrial membrane permeabi-
lization (MMP). Since mitochondrial permeabilization is
a relatively early event in the apoptosis, detecting this
event might be more useful in revealing the presence of
apoptotic cells than other assays, such as those that
measure caspase-3 activation or DNA fragmentation.
In vivo studies of induction of apoptosis in experimental
models and patients undergoing therapy have yet been
limited to histological examination, thus providing a
static picture of apoptosis, rather than an observation of
ongoing cell death. However, in vivo detection of
apoptosis is also hampered by the rapid clearance of
apoptotic cells by phagocytes [159]. Preclinical studies
on tumor cells analyzing the contribution of caspases to
anticancer therapy resistance have to our knowledge not
yet been published. However, inhibition or loss of cas-
pase expression has been proposed to confer resistance to
different anticancer drugs [160, 161]. The potential
impact of caspases and their activators on resistance is
also supported by ‘knock-out’ mouse models with distinct
variations of the Apaf1, caspase-3 or caspase-9 gene,
which are resistant to various apoptotic stimuli in dif-
ferent tissues [162–164].
Finally, alterations in the p53 gene and implications in
the induction of apoptosis represent one of the most studied
genetic events in cancer cells and are suggested to be
linked to chemosensitivity. Nevertheless contradicting
results were reported. For example, significant correlations
of overexpression of p53 and prognosis were published
[165] for squamous cell carcinomas, but no correlations
were found in another study [166].
Detailed analysis of the induction of apoptosis is now-
adays mainly integrated in comprehensive drug testing
platforms for preclinical testing of anticancer drug candi-
dates. Therein, the in vitro analysis of the mode of action
and efficiency of a drug candidate is the main focus.
Genomics
Cancers arise from a multistage process in which tumor
cells progressively acquire a sequential accumulation of
genetic alterations. The genomic changes occurring in the
transformation of normal cells to cancer cells influence
several genetic mechanisms. These events destabilize the
normal cellular homeostasis e.g. gains, losses or translo-
cations of large regions of chromosomes, single-nucleotide
substitutions, copy number changes and methylation
events. Among these alterations, intragenic mutations play
an important role in activating oncogenes or inactivating
tumor suppressor genes. This results in misregulation of
cellular signaling, e.g. proliferation and apoptosis and thus
generates a survival advantage for the cancer cell [167,
168]. Certain mutations may be associated with specific
types of cancers or may be common to several types of
cancers. Currently, most of our knowledge of these alter-
ations stems from studies of single genes in specific
cancers. A variety of high-throughput techniques has now
been developed for profiling and analysis of cellular net-
works, providing means to survey the cancer genome and
transcriptome. By the complete sequencing of the human
genome and progress in bioinformatical research, the
understanding of cancer-related genomic alterations and
expression patterns has grown. Nonetheless, understanding
of the complex basic patterns and functions of molecular
alterations on the genomic level are a great challenge.
Therefore, the main focus of oncogenomic profiling lies on
the analysis of DNA repair, mutation status, gene expres-
sion, gene copy number and genome stability (Fig. 4).
Based on the current knowledge of the oncogenomic
alterations existing in cancer genotypes, key mutations of
cancer development [169], new subclasses of cancer types
have been identified [170, 171] and even models for the
prediction of clinical outcome have been calculated [172,
173].
The prediction of response to therapy is a relatively new
field of oncogenomics. The strong heterogeneity of indi-
vidual tumors in terms of clinically observed drug response
is an important reason for the need for individualized,
molecular guided therapy, but also for the difficulties in
realizing this goal. There is accumulating evidence that
drug-specific response pathways are influenced by the
individual genotype and gene expression, which led to
efforts to identify gene signatures and gene mutations
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predictive for chemosensitivity. This will ultimately lead to
the development of strategies for patient-tailored antican-
cer therapy which are based on the individual molecular
profile of a tumor [172].
Mutation analysis
During the past decades, there have been great advances in
experimental methods for genome characterization built on
‘first-generation’ capillary-based DNA sequencing, also
known as Sanger sequencing [173]. These sequencing
methods can be crudely divided into a general and a tar-
geted approach. The products of both approaches are
amplified templates, either by multiplication in plasmids or
as PCR amplicons. Sequence determination is then per-
formed by high-resolution electrophoretic separation in a
capillary-based polymer gel. Bioinformatical software
converts these signals into DNA sequences and calculates
error probabilities for each base-call. Approaches, like the
second-generation parallel sequencing techniques
increased the throughput and decreased the cost of nucle-
otide resolution. Second-generation sequencing
technologies are based on the simultaneous detection of
nucleotides in arrayed amplified DNA products originating
from single DNA molecules [174]. Advanced technologies
like next-generation sequencing approaches are currently at
the front of research with great potentials to give new
insights in tumor heterogeneity and individual drug
responses. High-throughput sequencing technologies
including those created by Illumina (Illumina, Inc.), 454
(Roche Diagnostics Corp.) and SOLiD (Life Technolo-
gies), enable whole genome sequencing at an
unprecedented scale and dramatically reduced costs over
the gel capillary technology used in the human genome
project.
Advanced next-generation sequencing systems are
capable of sequencing a human genome at 309 coverage in
less than 1 week. These next-generation sequencing (NGS)
systems use parallel sequencing to generate hundreds of
millions of short (36- to 150-bp) DNA reads that can be
aligned to the human genome. Although a number of dif-
ferent NGS strategies have been developed, the paired-end
strategy from Illumina Inc. has become the tool of choice
for most cancer genome studies published to date. While
most cancer genome studies so far have focused on single
patients, this pattern is changing as a result of ongoing
international collaborations and decreases in the cost of
sequencing. The hope is that NGS data will shorten the
road to personalized medicine, in which treatments and
therapies are tailored to target the unique features of
individual tumors and tumor subpopulations [175] based
on mutations that define sensitivity and drug resistance
(http://www.cancerrxgene.org/).
The extensive genotyping of individual tumors dis-
played thousands of mutations in an individual cancer
genome [176]. The extent of genetic variation in the gen-
omes of the human population is far greater than had been
estimated [177]. While the impact of the vast majority of
these mutations currently remains unknown, basic and
translational research has pointed out, that a much smaller
group of mutations is not only necessary for the develop-
ment of cancer but is also required for the maintenance of
the tumors´ survival [178]. The presence of such ‘driver’
mutations sustains tumors and can simultaneously repre-
sent a cancer-specific target for therapy [179–182]. For
example, the mutations of the tumor suppressor genes
TP53 and EGFR are among of the most studied mutations
in cancer research with implications in tumor development,
progression and response to chemotherapy [183]. Several
mutations in genes, encoding for proteins involved in cell
signaling pathways, have a strong impact on the field of
targeted therapy. This area of cancer research is reviewed
elsewhere in detail [180, 184–190].
Individual alterations and differences in metabolism, in-
and efflux of xenobiotics and cellular signaling pathways
caused by mutations are some of the reasons for the
diversity in individual response to conventional chemo-
therapy [191]. The most common form of mutation in the
Fig. 4 Exemplary illustration
of different genomic approaches
used in translational research
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human genome is the single-nucleotide polymorphism
(SNP). Functional genomic polymorphisms in drug target
genes [193], metabolising enzymes [194] and DNA-repair
enzymes [195] may have important implications for drug
efficiency. Therefore, these sequence alterations are
determinants of variations in metabolism of drugs and
associated side effects, because they have an important
influence on the expression levels and activities of the
corresponding proteins [196]. A recent study found that
anticancer drug susceptibility-associated SNPs were asso-
ciated with the transcriptional expression level of genes as
potential master regulators [197]. A significant body of
evidence supports the concept of predicting drug efficiency
and side toxicity by SNP genotyping. For example, tran-
scriptional contributions of genetic polymorphisms to
cytotoxicity of cisplatin using human cell lines were listed
[198]. Furthermore, in 2010 a genome-wide identification
of chemo-sensitive SNP markers in colorectal cancer was
conducted by Kim and colleagues [199]. Besides the
characterization of the NCI60 panel regarding the mutation
status of 24 genes, causally implicated in oncogenesis and
drug response [200], the panel was also screened for
chemosensitivity associated SNPs. This resulted in several
studies dealing with the establishment of pharmacogenetic
markers [201, 202].The impact of polymorphisms in genes
involved in anticancer drug efficiency, response to che-
motherapy and potential side effects has been reviewed
elsewhere [203, 204]. Whereas the current knowledge
about SNPs provides us with invaluable tools to find and
understand significant associations between SNPs and drug
response, we do not fully understand the genetic com-
plexity of the attributes, underlying individual variability in
drug response. Interpretations of associated studies are
complicated by the number of genes, variants in each gene
and the frequency of a variant within a population. The
location of a variant SNP in the coding region, the regu-
latory region, or the non-coding region of the genome also
affects proteinexpression and function, in a way that is not
yet fully understood. Further advances in molecular biol-
ogy and bioinformatics will make it possible to
comprehensively understand the complex influence of
SNPs on gene expression, protein expression and finally
protein function. This will add its part to the understanding
of the complex network of determinants underlying indi-
vidual response to anticancer therapy.
Furthermore, FISH analysis is routinely performed to
assess general cytogenetics and in particular disease-rela-
ted chromosomal disorders, e.g. chronic myelogenous
leukemia, acute lymphoblastic leukemia and Down syn-
drome. For prediction of response to anticancer therapy,
the FISH technique has been primarily used to determine
the copy number of the HER-2 gene to select for HER-2
targeted therapies such as trastuzumab and lapatinib in
breast cancer. Therefore, the determination of HER-2 gene
amplification by FISH technique is widely used in clinical
trials evaluating HER-2 targeted therapies [180–183]. In
the analysis of response to targeted anticancer therapy,
FISH is mainly used to investigate relationships between
the copy number of a gene, encoding a target protein and
individual response to therapy [184, 185].
DNA microarray profiling
A DNA microarray is a multiplex technology used to
simultaneously measure expression levels of thousands of
genes. RT-PCR applications are generally the techniques of
choice, based on the enhanced sensitivity with the ability to
detect RNA over a seven-log range. This technology has
been miniaturized on small silicon chips or glass slides
with the feasibility to accommodate over 30,000 oligonu-
cleotides or cDNAs and has thus adapted to high-
throughput performance. The huge amount of data pro-
duced by those experiments is being analyzed by pattern
recognition software, using clustering algorithms for the
identification of groups of genes whose expression varies in
the same way between groups. Bioinformatic data mining
has the potential to reveal unknown patterns of relation-
ships between genes, in context to response mechanisms to
anticancer therapy.
The identification of gene sets with a functional role in
chemosensitivity may provide assistance in the choice of
patient-tailored therapeutic regimens and for therapeutic
intervention in drug-resistant disease.
Since more than 100,000 compounds were screened for
anticancer activity patterns against the NCI60 cell line
panel and the resulting data has revealed information on the
mechanisms of action and resistance of those compounds
[205–207], several genomic studies have been conducted
using the well characterized NCI60 cell line panel as a
basis. The p53 tumor suppressor pathway [208], membrane
transporters and channels [209], reductase enzyme
expression [210], EGFR expression and amplification
[211], P450 enzyme expression [212] and MRP expression
[213] are some examples for the investigations of rela-
tionships between distinct gene expression patterns and
response to anticancer therapy based on the NCI60 panel.
Among others, Weinstein and colleagues have analyzed
gene expression patterns of the NCI60 panel on the basis of
activity patterns of compounds [207, 214]. To improve the
reliability of gene signatures predictive for chemosensi-
tivity, robust methods for combining microarray expression
data with NCI60 chemosensitivity data were developed.
Algorithms for predicting chemosensitivity were optimized
based on different bioinformatic filter- and cluster
approaches [215, 216]. The bioinformatic approach called
the co-expression extrapolation (COXEN) algorithm has
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been shown to be useful in the NCI60 panel to predict
chemosensitivity, even in cell lines of histological types
not included in panel. That led to the question, whether this
approach could be used to predict drug sensitivity in dif-
ferent patient’s primary tumors. A modification of the
COXEN algorithm has been demonstrated to be potentially
applicable to bypass the intermediate animal model and
achieve predictability of response to anticancer therapy in
the clinic situation [217].
Results from the NCI60 panel were also observed in
other cell line panels, e.g. the classification of drugs based
on their modes of action [218]. Based on these results,
Nakatsu et al. complemented the JFCR-39 cell line panel
and developed an integrated database of chemosensitivity
correlated with gene expression for this new cell line
panel, called JFCR-45. This revealed candidate genes
which may be related to chemosensitivity. To proof this,
the ability of these candidate genes to alter chemosensi-
tivity after being individually over-expressed was
examined [219]. Another panel consisting of 30 cell lines
was also used in a study, which focused on chemoresis-
tance to in vivo concentrations achieved by anticancer
drugs. Gene expression patterns provided 76 new candi-
date genes with associations to multidrug-resistance. This
may allow prediction of response to anticancer therapy in
a clinical situation [220]. Sekine et al. published in 2007
[221], highlighting genes which potentially regulate
chemosensitivity of tumor cell lines to anticancer therapy.
Furthermore, comprehensive studies correlating gene
expression patterns and chemosensitivity were conducted
using human tumor xenografts [88, 89, 222]. A genome-
wide study, analyzed gene expression profiles of 85 cancer
xenografts in mice that had been established from nine
different human organs. The applied cDNA microarray
consisted of 23,040 genes, used to study those xenografts.
The study resulted in the identification of 1,578 genes
whose expression levels correlated significantly with
chemosensitivity [223]. All these studies suggest that the
combination of unbiased genome-wide chemosensitivity
analysis using array-based approaches may identify can-
didate genes or gene sets with the capacity to predict
cancer cell chemosensitivity. It is important, that these
candidate genes or gene sets identified in these functional
approaches still require extensive validation in vivo before
they can be considered as putative biomarkers and find
application in the clinical setting. Therefore, several
studies were conducted in patient cohorts to identify pre-
dictive biomarker for anticancer therapy directly in the
clinical setting. Clinical trials were carried out for differ-
ent tumor entities, e.g. colorectal cancer [224, 225],
oesophageal cancer [226], epithelial ovarian cancer [227],
pancreatic cancer [228] and breast cancer [229, 230].
These studies reported on gene signatures that may enable
prediction of the response to anticancer therapy. Even
though these studies were carried out directly in patient
cohorts, the resulting predictive signatures have to be
validated in independent studies, with a more significant
number of patients. The instability of gene expression
signatures derived merely from associative studies has
been documented [231–233] and contributes to failed
attempts to identify gene expression patterns predictive of
response to anticancer therapy. Consequently, DNA
microarray analyses of small clinical trial cohorts may not
yield gene signatures with power sufficient to predict
chemosensitivity [234]. Furthermore, tissue sampling and
quality have a major impact on profiling results, due to the
fact that transcriptional profiles are the sum of mRNA
expression contributed by all tissue components [170].
Individual tumor mRNA expression heterogeneity and the
varying tumor content in clinical samples, may give a
significantly impaired transcriptional profile among sam-
ples [235]. The interpretation of microarray results is also
difficult in that complex bioanalytic and bioinformatical
analysis techniques are used, which are not yet fully
standardized. Nonetheless, the analysis of gene expression
patterns greatly contributes to the understanding of the
complex cellular mechanisms underlying individual
response to anticancer therapy.
Currently, commercialized microarray-based multigene
assays are already available. For example, the MammaPrint
assay (Agendia BV, Amsterdam, The Netherlands) com-
prising 70 genes, which is currently designed as a pure
prognostic assay for women under the age of 61 with either
ER-positive or ER-negative, lymph node negative breast
cancer [236]. This assay has not yet been shown to be able
to predict sensitivity to anticancer treatment. The oncotype
DXTM is a 21-gene, prognostic and predictive assay that
determines the 10-year risk for disease recurrence in
patients with ER-positive, lymph node negative tumors. In
contrast, this assay has been reported to predict benefit
from tamoxifen treatment in patients with a low or inter-
mediate risk score and benefit from chemotherapy in those
with a high-risk score [237]. A combination of several
pharmacogenomic gene sets, designed primarily as a pre-
dictive test for guiding selection of therapy is called the
NuvoSelectTM assay. One of the used gene sets consisting
of 30 genes predicts response to preoperative combination
treatment with paclitaxel, 5-fluorouracil, doxorubicin, and
cyclophosphamide (TFAC). Another gene set predicts
clinical outcome after 5 years of endocrine therapy [238].
In summary, the collection of huge databases of gene
expression studies will hopefully reveal a comprehensive
picture of the genomics of cancer and contribute its part to
individualized anticancer therapy.
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Proteomics
Functionally, cancer is a genomic as well as a proteomic
disease. While the basic information for the production of
proteins is encoded by the genome, only subsets of the
possible protein products abundant in the cell are displayed
in the genetic code. Finally, the structure of protein pro-
ducts and their functional status often depend on post-
translational modifications, such as phosphorylation, gly-
cosylation and proteolytic cleavage that are not reflected in
their genomic sequences. Furthermore, gene expression
often does not correlate with the protein expression or the
functionality of the encoded protein [239, 240]. Since,
cellular signal transduction is mostly a post-translationally
driven process, it seems obvious to directly investigate the
protein-driven signaling cascades by the use of proteomics
[241]. Proteomics is a recent member of the ‘omics’ family
and describes the study of the wide complement of cellular
proteins, their subcellular localization, turnover and inter-
action with other proteins. In contrast to the genome, the
proteome is at a constant flux due to diverse environmental
influences. Therefore, the proteome is significantly more
challenging to map, compared to the genome [242].
Alterations within the proteome also have a potentially
higher functional impact than modifications in the genome,
because they are more likely to contribute to a drug-
resistant phenotype [243].The analysis of proteins and
protein networks in cancer using proteomic technologies is
known as oncoproteomics (Fig. 5). Given that the prote-
ome of a cell is responsible for key-biologic processes and
therefore also makes up the bulk of pharmaceutical targets,
oncoproteomics has the potential to revolutionize clinical
practice. This includes cancer diagnosis, development and
individualized selection of therapies that target exclusively
the cancer-specific protein networks, and real-time
assessment of therapeutic efficiency and toxicity. Proteins
are traditionally measured using low-throughput techniques
such as western blotting, in situ hybridization and immu-
nohistochemical staining [244]. Two-dimensional (2D) gel
electrophoresis is a widely used technique in proteomic
research, due to its high resolving power that permits
simultaneous visualization of primary and post-transla-
tionally modified gene products in a single gel [245, 246].
This technology has been used to separate proteins on the
basis of their size and charge. In combination with mass
spectrometry for protein identification this is a widely used
approach for the discovery of several biomarker candi-
dates. Matrix-assisted laser desorption and ionization with
time-of-flight detection mass spectrometry (MALDI-TOF),
surface-enhanced laser desorption and ionization with
time-of-flight spectrometry (SELDI-TOF) and antibody-
based protein microarrays are modern methods for a rapid
and more sensitive high-throughput detection and identifi-
cation of both known and unknown proteins [247]. In
contrast to mass spectrometry-based biomarker discovery,
antibody-based profiling requires prior knowledge of the
proteins that are going to be investigated. Therefore, the
identification of previously unknown protein biomarker
candidates is restricted to MS-based discovery approaches.
Antibody-based approaches, such as protein microarrays
became more and more important with the introduction of
targeted anticancer therapy. These technologies are
potentially able to map the activation status of cellular
signaling pathways comprehensively, which will have a
strong impact on individualized treatment concepts and
monitoring of response to therapy. Nearly all proteomic
techniques that are usually used for molecular analysis in
several biomedical fields are also applied in the study of
response to therapy in human cancers [248–250]. Onco-
proteomics will play an important role in gaining new
insights into cancer development and progression as well
as in the discovery and validation of new protein targets for
diagnostics and prediction of response to anticancer ther-
apy [251–253]. Furthermore it will be a great challenge to
acclimatize proteomic technologies for regular use in
clinical laboratories.
2D electrophoresis
Two-dimensional gel electrophoresis (2DE) is one of the
oldest approaches and one of the most powerful protein
separation methods available today. The first-dimensional
separation of samples is achieved by isoelectric focusing
(IEF), which separates proteins on the basis of their charge.
Two types of IEF techniques are currently used: the
immobilized pH gradient (IPG) technique; and the non-
equilibrium pH gradient gel electrophoresis (NEPHGE).
The second-dimensional separation is performed using
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
[254]. The 2DE provides the capability to qualitatively and
quantitatively resolve complex protein mixtures to unique
spots [255, 256]. The measured protein patterns can be
analyzed using sophisticated, bioinformatical software to
reveal those proteins that are differentially expressed
between samples.
2D-DIGE is an important proteomic tool, especially for
translational research involved in biomarker discovery.
When absolute biological variation between samples is the
main objective, as it is in biomarker discovery, 2D-DIGE is
still one of the methods of choice [257]. Several studies
were published, identifying novel prognostic or predictive
biomarkers, e.g. biomarkers of drug-resistance [258–261].
First experiments, to study resistance to anticancer therapy
using 2DE techniques were performed back in 1986, when
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Shen et al. [262] investigated the mechanisms of multidrug
resistance in human cancer cells. Since then, experimental
techniques have continuously been improved and modified
for various study designs [263, 264]. For example, Tanaka
et al. adapted the 2DE technique for a comparative pro-
teomic analysis of basic proteins. In this study, cancer cell
lines were analyzed with regard to their chemosensitivity,
using a radical-free and highly reducing method of two-
dimensional polyacrylamide gel electrophoresis [265]. This
technique is reported to have a superior ability in the
separation of basic proteins and the quantification of post-
translational modifications, compared to traditional 2DE
[266]. Different prefractionation methods, prior to 2DE
analysis, as well as various combinations of analysis
technique have also been developed to gain detailed
knowledge of cellular mechanisms involved in response to
anticancer therapy. Based upon these developments,
detailed studies of different cellular components and pro-
tein signaling networks have also been conducted, e.g. the
subcellular proteome [267, 268], the phosphoproteome
[269], mitochondrial proteome [270] .Using comparative
proteomic approaches, long lists of differentially expressed
proteins, potentially involved in chemoresistance mecha-
nisms were published, and reviewed by Zhang et al. [271].
Besides studies based on secondary cell lines, these tech-
niques also found application in the clinical setting [272,
273]. In many studies, biomarker candidates were validated
by alternative, more specific techniques such as RT-PCR
and Northern blot at the mRNA level or Western blot and
immunohistochemistry at the protein level. The identified
proteins belonged to a variety of different classes of pro-
teins. However, the limitations of this method include
limited reproducibility and inability to detect low abundant
proteins [274]. These low levels may result in undetectable
proteins which significantly limit the application of this
method to clinical samples. The combination of 2DE based
with liquid chromatographic (LC) protein separation tech-
niques [e.g. 296] and complete gel-free LC–MS approaches
are more and more recognized.
Chromatographic techniques
An alternative, non-gel-based, protein separation approach
to 2DE is Liquid Chromatography (LC) [275]. Basically,
the components are separated using two phases, a station-
ary phase and a mobile phase. The procedure is mainly
described by the elution of the different components at
different rates, due to a varying affinity to interact with the
used matrix, which results in a physicochemical separation.
This technology is basically used for protein or peptide
separations, prior to MS analysis and has been improved to
handle proteomic analyses of complex samples [276].
Various chromatography techniques have been developed
as methods for protein separation, e.g. reversed-phase
[277], cation exchange [278], anion exchange [279],
biphasic ion-exchange [280] or size-exclusion [281]. Sin-
gle- and multidimensional LC can directly be interfaced
with the mass spectrometry (MS), enabling automated
analysis of large amounts of data for subsequent protein
identification [282]. Another 2D chromatographic strategy
termed multidimensional protein identification technology
(MudPIT) has been extensively applied to proteomic ana-
lysis. Mud-PIT is in principle a technique in which two
liquid chromatographic steps are interfaced back-to-back in
a fused silica capillary to permit two-dimensional high-
performance liquid chromatography, combined with mass
spectrometry for protein identification [283, 284]. How-
ever, the application of tryptic digestion of proteins in these
technologies introduces some limitations. Unfortunately,
the tryptic digestion of protein samples results in a loss of
basic information about the intact proteins, e.g. post-
translational modifications. Furthermore, low abundance
proteins from a complex mixture may not be detectable in
the presence of various peptides originating from other
proteins. Therefore, the separation of intact proteins by
liquid chromatography may offer advantages over tryptic
approaches and the use of gel-based methods. In general,
these technologies show advantages over gel-based tech-
niques with regard to speed, sensitivity, scope of analysis
Fig. 5 Exemplary illustration
of different proteomic
approaches used in translational
research
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and dynamic range [285]. In the field of oncoproteomics
these methods have been integrated in the mass spec-
trometry-based discovery and characterization of novel
biomarker candidates for guiding individualized anticancer
therapy (e.g.) [286, 287].
Mass spectrometry (MALDI TOF MS, SELDI
TOF MS)
Mass spectrometry is a method of choice for analytical
characterization of potential drug molecules and protein
identification. This technology is widely used to detect and
identify the chemical composition of samples, after ioni-
zation, on the basis of their mass-to-charge ratio (m/z). As
described earlier, mass spectrometry is often combined
with different protein separation techniques to discovery of
protein biomarker. Many variants of mass spectrometry-
based approaches have been developed for gel-free pro-
teomic analysis. These methodologies apply different pre-
fractionation techniques, such as selective surface binding
(SELDI), magnetic bead pre-fractionation or liquid chro-
matography (LC-MALDI). The basic principle of the
surface-enhanced laser desorption/ionization- time of flight
(SELDI-TOF) and the matrix-assisted laser desorption/
ionization (MALDI) techniques is the fact that the sample
is pulsed with laser energy causing proteins or protein
fragments to ionize, and fly through a vacuum tube to the
detector plate. Their time of flight is affected by the mass
of the particle and its charge (m/z ratio). The detector plate
records the intensity of the signal at a given m/z value, and
a spectrum is generated. The different peaks in the spec-
trum correspond to different m/z protein species. SELDI-
TOF is a proteomic technology used for the quantitative
analysis of protein mixtures after selectively capturing
proteins on pretreated surfaces. In contrast to the MALDI
technology, the SELDI technology uses selective surfaces
for binding a subset of proteins based on absorption, par-
tition, electrostatic interaction or affinity chromatography
on a solid-phase protein chip surface. Therefore, stainless
steel or aluminum-based chips are coated with chemicals
(e.g., anionic, cationic, hydrophobic, hydrophilic, or
immobilized metal affinity) or biological substances (e.g.,
antibodies, antigen binding fragments such as scFv, or
receptor) to capture protein samples based on their intrinsic
properties. These pre-fractionation steps enable the detec-
tion of low abundant proteins. Until now, SELDI has
mainly been used to characterize patients at risk of the
development of cancer based on the direct analysis of body
fluids like serum, plasma, and urine [288–290]. Nonethe-
less, there are approaches to use SELDI-TOF as a clinical
proteomics tool for the identification of protein biomarker
candidates, being predictive for response to anticancer
therapy [90, 291–293].
In general, MALDI techniques immobilize protein
samples in an energy absorbing matrix. The entire reper-
toire of proteins in the sample interacts with the matrix
from which a selected subset of proteins is bound to, a
function of the composition of the selected matrix. The
matrix chemicals absorb energy, which is subsequently
passed to the sample proteins. Protein structural informa-
tion, such as peptide molecular weight, amino-acid
sequence composition, type and location of post-transla-
tional modification, could be obtained by MS analysis.
Two MS technologies are common and widely used, the
matrix-assisted laser desorption ionization time of- flight
mass spectrometry (MALDI–TOF–MS) and the electro-
spray ionization mass spectrometry (ESI–MS). MALDI–
TOF–MS generates ions from solid-phase samples and
measures their mass in a flight tube, whereas ESI–MS
generates ions from liquid samples and measures their
mass using either quadrupole or time of flight detector.
MALDI–MS is the most commonly used technique for
peptide mass fingerprinting [294, 295]. MALDI–MS is a
fast, robust, easy to perform, sensitive (low fmol range),
and accurate (low ppm range) technology, which can be
adapted to high-throughput [296]. LC-MALDI approaches
have also been used to identify protein biomarker for the
prediction of response to anticancer therapy. These studies
were performed using cell lines, as well as patient’s tumor
and serum samples [297–301]. Mass spectrometry tech-
nologies in combination with protein separation techniques
have the ability to investigate complex patterns of protein
expression and modification. Despite the complexity of the
human proteom, the constantly improved proteomic tech-
nologies will ultimately enable the measurement of
individual molecular profiles of patients on the protein
level, with the potential to guide personalized medicine.
Immunohistochemistry
Similar to the western blot technology, immunohisto-
chemistry is a well-known method which has developed
over the years with respect to reproducibility and sensi-
tivity. In 1941 already, Coons et al. [302] published a paper
describing an immunofluorescence technique for detecting
cellular antigens in tissue sections, which marked the
beginning of immunohistochemistry (IHC). The funda-
mental concept behind IHC is the detection of antigens
within tissue sections using specific antibodies. Once
antigen–antibody binding occurs, a colored histochemical
reaction becomes visible by light microscopy or in the case
of fluorochromes using ultraviolet light. Immunohisto-
chemistry (IHC) has long been used as an adjunctive
diagnostic tool in a variety of cancers. It has provided
clinicians with correlative insight into potential prognosis
and differential diagnosis. The initially simple method of
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IHC has become more complex over the years. Currently,
extremely sensitive methods are available to detect one or
multiple antigens simultaneously or even to examine hun-
dreds of tissues in the same section for the presence of a
particular Antigen (microarray technology).
Automation using automated slide stainer increased
throughput and reproducibility. Automated staining
according to very stringent and standardized conditions has
become more and more important since the introduction of
targeted anticancer therapy, wherein target expression is
one of the essential preconditions. For example, HER2
testing has become an important part of the clinical eval-
uation of all breast cancer patients throughout different
countries, and accurate HER2 results are necessary for
identifying patients who benefit from HER2-targeted
therapy. IHC analysis is deeply integrated in breast cancer
treatment by being able to determine the HER-2 status, the
testing of progesterone receptor, estrogen receptor and the
proliferation marker Ki-67 [303, 304]. Hence IHC is rou-
tinely used to predict response to both HER-2 and
hormonal targeted therapies, but is not yet suitable for the
prediction of either efficiency or toxicity of anticancer
drugs.
Furthermore, IHC is often being used to validate find-
ings from alternative proteomic studies. For example the
validation of prognostic and predictive protein biomarker
candidates derived from cell line experiments is commonly
performed in clinical tumor samples [305–307]. The vali-
dation of proteomic-based discovery using clinical
specimen is reviewed by Hewitt et al. [308]. Although,
antibody signals can be directly assigned to cellular
localizations and thus laser microdissection is not required,
IHC results are nonetheless influenced by pre-analytic tis-
sue processing and antigen retrieval. Inconsistent quality of
IHC reagents and antibodies is also discussed to influence
robustness of IHC results [309]. Despite automation and
knowledge, IHC, still lacks uniformity of technique,
appropriate controls, and standardization of antibodies and
grading techniques, making it difficult to compare results
across institutions, laboratories and experiments. The sta-
tistical analysis of IHC-based multiple markers may be
complicated by the nonlinear nature of IHC staining, the
impact of different slide scoring thresholds for different
immunostains and different subcellular localization of
markers. Limitations of IHC have been addressed by other
techniques, including isotopic labeling and in situ hybrid-
ization, which allow for more quantitative analysis of
variations in protein expression.
Protein microarrays
Protein microarrays, one emerging class of proteomic
technologies, have broad applications for discovery and
quantitative analysis of protein expression patterns [310,
311]. This technology is uniquely suited to generate an
overview map of known cellular signaling proteins and
their activation status, reflecting the state of information
flow through cellular networks in individual specimens. In
the simplest sense, protein microarrays are immobilized
protein spots [312, 313]. Thus, proteins can be arrayed on
solid surfaces, capillary systems or immobilized on beads
[314, 315]. The spots may be homogeneous or heteroge-
neous and may consist of a bait molecule, such as an
antibody, a cell or phage lysate, a nucleic acid, drug or a
recombinant protein or peptide [316]. In the array, detec-
tion is achieved by probing with a tagged antibody, ligand
or serum/cell lysate. The most advanced format of this
technique is the antibody-microarray, in which the targeted
proteins are detected by specific antibodies, which were
coated on solid surfaces [317]. The reverse-phase protein
microarrays (RPPA) for example, immobilize one sample
per array spot, enabling an array to comprise hundreds of
different cellular lysates or patient samples. The detection
of proteins is conducted using phosphospecific and total
protein antibodies to determine the activation status of key
signaling molecules. This technology has been widely
been used to analyze distinct cellular signaling pathways
or to screen cell line panels as well as collections of
clinical specimens for disease-related protein expression
patterns. For example, Jones et al. [318] comprehensively
analyzed the protein interaction network for the ErbB
receptor family, which may have implications in epidermal
growth factor receptor targeted anticancer therapy. Chan
et al. [319], first showed the application of multiplexed
reverse-phase protein microarrays to the study of signaling
kinetics and pathway delineation in a leukemic T lym-
phocytes cell line after activation of certain receptors. An
example of for the use of RPPA to screen protein
expression patterns in cell line panels is a study of Nish-
izuka et al. [320], screening the NCI60 cell line panel
using a reverse-phase protein lysate microarray. A finding
from this study was that the patterns of protein expression
compared with those obtained for the same genes at the
mRNA level showed a striking regularity. Cell-structure-
related proteins almost invariably showed a high correla-
tion between mRNA and protein levels across the NCI60
cell lines, whereas non-cell-structure-related proteins
showed poor correlations. They also proposed that, this
technology can be expected to contribute significantly to
the identification of molecular markers and targets for
individualized anticancer therapy. On this basis, Ma et al.
[321] determined whether proteomic signatures of
untreated cancer cells were sufficient for the prediction of
drug response using the NCI60 panel. In this study, a
machine learning model system was developed to classify
cell line chemosensitivity exclusively based on RPPA
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proteomic profiling. The accuracy of chemosensitivity
prediction of all the evaluated 118 anticancer agents was
significantly higher (P \ 0.02) than that of random pre-
diction. This study provided a basis for the prediction of
drug response based on protein markers in the untreated
tumor. Cell line panels find broad application in the pro-
teomic analysis of individual chemosensitivity and drug
discovery [322–325]. Protein microarray platforms that
can provide a quantitative, multiplexed read-out for cel-
lular signaling and that can utilize microscopic quantities
of tissue specimens for upfront analysis are needed for the
implementation of this technology in the clinical situation
[326] Therefore, the RPPA format has been improved to
be able to measure the abundance of many specific pro-
teins in complex solutions and has been adapted to use of
very small amounts of protein, [327]. Thus, this technol-
ogy is well suited for signal transduction profiling of
clinical samples, e.g. biopsy specimens [316, 328, 329].
The identification of critical nodes or interactions within
these networks is essential to drug development and the
design of individualized anticancer therapy [330], espe-
cially with targeted drugs [331, 332]. Using breast cancer
as an example, Wulfkuhle et al. [241] stated that, phos-
phoprotein-driven cellular signaling events represent most
of the new molecular targets for anticancer therapy.
Therefore, the application of reverse-phase protein
microarray technology for the study of ongoing signaling
activity within breast tumor specimens holds great poten-
tial for elucidating and profiling signaling activity in real-
time for patient-tailored therapy. Moreover, their data
demonstrate the requirement of laser capture microdis-
section (LCM) for analysis and reveal the metastasis-
specific changes that occur within a new microenviron-
ment. Microdissection should be a necessary component of
molecular analysis since dramatic changes within specific
protein phosphorylation levels were noted between a
majority of the undissected and microdissected samples.
Laser capture microdissection technology permits a
selection of a homogenous tumor population from a field
of normal-appearing cells and vice versa, to improve the
accuracy of comparative proteomics studies. Furthermore,
Haab et al. [327] noted that, the sensitivity of individual
antibody–antigen interactions for any given detection
system are highly dependent on the relative abundance of
the antigen–antibody species and the binding affinities
between the probe antibodies and the immobilized anti-
gens. Liotta et al. [333] reported on the analytical
challenges faced by protein arrays and proposed a practical
guide for optimizing construction and study design.
Additionally, a difficulty is associated with preserving
proteins in their biologically active conformation before
analysis. This will further limit the application of this
technology as a routine proteomic strategy, unless clinical
samples are routinely taken by the use of highly specified
procedures. The broad application of protein arrays in
personalized medicine is also impaired by the costs of
producing antibodies and the limited availability of anti-
bodies with high specificity and high affinity for the target.
Nevertheless, protein microarrays in combination with
technologies such as LCM and high standardization will
greatly contribute to the improved description of the multi-
factorial network, underlying individual response to anti-
cancer therapy and will allow the design of personalized
medicine.
Discussion
For most of the history of medicine, doctors relied on their
senses—mainly vision, hearing, and touch—to diagnose
illness and monitor a patient’s condition. Since then, bio-
medical research has made huge progress in diagnosis and
treatment strategies. The traditional trial-and-error practice
of medicine is progressively eroding in favor of more pre-
cise marker-assisted diagnosis and safer and more effective
molecularly guided treatment of disease. The aim of per-
sonalized medicine is to tailor disease detection, diagnosis
and therapy to each individual´s profile, using molecular
profiles to predict disease development, progression, clini-
cal outcome and response to anticancer therapy. Recent
advances in high-throughput technologies have raised new
opportunities in the fields of personalized- and predictive
medicine. Thus, enabling researchers to screen the whole
genome, proteome, transcriptome, and metabolome for
biomarkers, in tumor tissues and body fluids [334]. In
addition, new cellular models such as 3D organoid cultures
or spheroid systems opened new opportunities in drug dis-
covery and translational research. These models reflect the
in vivo situation much better than common 2D models
which are however, well suitable for high-throughput
screenings. The introduction of modern technologies such
as mass spectrometry and protein and DNA arrays, com-
bined with the understanding of the human genome, has
enabled simultaneous examination of thousands of proteins
and genes in single experiments. These technologies are
capable of performing parallel analysis, in contrast to serial
analysis conducted with older methods. Due to the variety
of data points, they provide opportunities to identify dis-
tinguishing patterns for cancer diagnosis and classification
as well as for prediction of response to anticancer therapies.
Furthermore, these technologies provide the means by
which new tumor markers could be discovered. At the
current stage, the molecular prediction of response to anti-
cancer therapy is more exploratory, aiming at advancing
scientific knowledge within clinical investigations rather
than routine in clinical practice.
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Although numerous biomarkers have been discovered,
only a handful of them, such as HER2 amplification,
BCR-ABL translocation, KRAS, BRAF and EGFR
mutations have been validated for the use in the clinical
reality [335].
Molecular research in human tumors is currently pre-
dominantly performed retrospectively, using residual tissue
specimens obtained from surgical resection procedures.
Those tissues are used for generating hypotheses regarding
the clinical relevance of the observed markers in the
studied patient populations, target validation, and assay
optimization. Often these tissue samples are obtained by
core needle biopsies, e.g. fine needle aspiration, resulting in
small sample amounts, which are often insufficient for
comprehensive molecular analysis with currently available
technologies. Therefore, the miniaturization of new
emerging technologies is urgently needed.
Furthermore, several studies have shown that tissue
samples change their molecular profiles and start degrading
immediately after resection from the patient’s blood sup-
ply. Several exogenous factors such as ischemia time,
drugs administered during surgery and processing proto-
cols have been identified, which affect the molecular and
genetic profiles of human tissue samples before, during and
after the surgical resection [336]. We propose that tissue
samples that reflect molecular reality are a requirement to
enable efficient cancer drug profiling and biomarker dis-
covery [337]. Besides technology-based challenges,
regulatory issues are also limiting factors in the develop-
ment of personalized medicine and predictive biomarkers.
The clinical validation of putative functional regulators of
drug response will run the risk of failure similar to other
biomarker development efforts unless strict reporting
guidelines are adhered to. Finally, the NCI-EORTC rec-
ommends that predictive biomarker studies require even
stricter considerations, requiring validation in large ran-
domized trials with sufficient power to detect drug-specific
differences in tumor response [192]. Using, combining and
further improving state of the art technologies and estab-
lishing stringent guidelines, the individualization of
anticancer therapy especially in second-line treatment, will
become accomplishable.
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